These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 32207836)

  • 1. Oral NAloxone to overcome the moRphine effect in acute COronary syndrome patients treated with TICagrelor - NARCOTIC trial.
    Niezgoda P; Barańska MA; Sikora J; Sobczak P; Buszko K; Sikora A; Marszałł MP; Navarese EP; Jilma B; Kubica J
    Cardiol J; 2022; 29(3):432-440. PubMed ID: 32207836
    [TBL] [Abstract][Full Text] [Related]  

  • 2. METoclopramide Administration as a Strategy to Overcome MORPHine-ticagrelOr Interaction in PatientS with Unstable Angina PectorIS-The METAMORPHOSIS Trial.
    Sikora J; Niezgoda P; Barańska M; Buszko K; Skibińska N; Sroka W; Pstrągowski K; Siller-Matula J; Bernd J; Gorog D; Navarese EP; Marszałł MP; Kubica J
    Thromb Haemost; 2018 Dec; 118(12):2126-2133. PubMed ID: 30453344
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of intravenous fentanyl compared with morphine on ticagrelor absorption and platelet inhibition in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: rationale and design of the PERSEUS randomized trial.
    Degrauwe S; Roffi M; Lauriers N; Muller O; Masci PG; Valgimigli M; Iglesias JF
    Eur Heart J Cardiovasc Pharmacother; 2019 Jul; 5(3):158-163. PubMed ID: 30101278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The MOVEMENT Trial.
    Holm M; Tornvall P; Henareh L; Jensen U; Golster N; Alström P; Santos-Pardo I; Witt N; Fedchenko N; Venetsanos D; Beck O; van der Linden J
    J Am Heart Assoc; 2019 Jan; 8(2):e010152. PubMed ID: 30636504
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Morphine delays and attenuates ticagrelor exposure and action in patients with myocardial infarction: the randomized, double-blind, placebo-controlled IMPRESSION trial.
    Kubica J; Adamski P; Ostrowska M; Sikora J; Kubica JM; Sroka WD; Stankowska K; Buszko K; Navarese EP; Jilma B; Siller-Matula JM; Marszałł MP; Rość D; Koziński M
    Eur Heart J; 2016 Jan; 37(3):245-52. PubMed ID: 26491112
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of Methylnaltrexone on Ticagrelor-Induced Antiplatelet Effects in Coronary Artery Disease Patients Treated With Morphine.
    Franchi F; Rollini F; Park Y; Hu J; Kureti M; Rivas Rios J; Faz G; Yaranov D; Been L; Pineda AM; Suryadevara S; Soffer D; Zenni MM; Bass TA; Angiolillo DJ
    JACC Cardiovasc Interv; 2019 Aug; 12(16):1538-1549. PubMed ID: 31377269
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of Escalating Loading Dose Regimens of Ticagrelor in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: Results of a Prospective Randomized Pharmacokinetic and Pharmacodynamic Investigation.
    Franchi F; Rollini F; Cho JR; Bhatti M; DeGroat C; Ferrante E; Dunn EC; Nanavati A; Carraway E; Suryadevara S; Zenni MM; Guzman LA; Bass TA; Angiolillo DJ
    JACC Cardiovasc Interv; 2015 Sep; 8(11):1457-1467. PubMed ID: 26404199
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of Morphine on Pharmacokinetics and Pharmacodynamics of Ticagrelor in Patients with Acute Myocardial Infarction (IMPRESSION): study protocol for a randomized controlled trial.
    Kubica J; Adamski P; Ostrowska M; Koziński M; Obońska K; Laskowska E; Obońska E; Grześk G; Winiarski P; Paciorek P
    Trials; 2015 Apr; 16():198. PubMed ID: 25925591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative effects of fentanyl versus morphine on platelet inhibition induced by ticagrelor in patients with ST-segment elevation myocardial infarction: Full results of the PERSEUS randomized trial.
    Iglesias JF; Valgimigli M; Carbone F; Lauriers N; Masci PG; Degrauwe S
    Cardiol J; 2022; 29(4):591-600. PubMed ID: 35762079
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacodynamics and pharmacokinetics of ticagrelor vs. clopidogrel in patients with acute coronary syndromes and chronic kidney disease.
    Wang H; Qi J; Li Y; Tang Y; Li C; Li J; Han Y
    Br J Clin Pharmacol; 2018 Jan; 84(1):88-96. PubMed ID: 28921624
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Crushed sublingual versus oral ticagrelor administration strategies in patients with unstable angina. A pharmacokinetic/pharmacodynamic study.
    Niezgoda P; Sikora J; Barańska M; Sikora A; Buszko K; Siemińska E; Marszałł MP; Siller-Matula JM; Jilma B; Alexopoulos D; Fabiszak T; Kubica J
    Thromb Haemost; 2017 Apr; 117(4):718-726. PubMed ID: 28203684
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and pharmacodynamics of ticagrelor in patients with stable coronary artery disease: results from the ONSET-OFFSET and RESPOND studies.
    Husted SE; Storey RF; Bliden K; Tantry US; Høimark L; Butler K; Wei C; Teng R; Gurbel PA
    Clin Pharmacokinet; 2012 Jun; 51(6):397-409. PubMed ID: 22515556
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chewing versus Swallowing Ticagrelor to Accelerate Platelet Inhibition in Acute Coronary Syndrome - the CHEERS study. For The PLATIS (Platelets and Thrombosis in Sheba) Study Group.
    Asher E; Frydman S; Katz M; Regev E; Sabbag A; Mazin I; Abu-Much A; Kukuy A; Mazo A; Erez A; Berkovitch A; Narodistky M; Barbash I; Segev A; Beigel R; Matetzky S
    Thromb Haemost; 2017 Apr; 117(4):727-733. PubMed ID: 28150850
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacodynamic Effects of Ticagrelor Dosing Regimens in Patients on Maintenance Ticagrelor Therapy: Results From a Prospective, Randomized, Double-Blind Investigation.
    Cho JR; Rollini F; Franchi F; DeGroat C; Bhatti M; Dunn EC; Ferrante E; Muniz-Lozano A; Suryadevara S; Zenni MM; Guzman LA; Bass TA; Angiolillo DJ
    JACC Cardiovasc Interv; 2015 Jul; 8(8):1075-1083. PubMed ID: 26117466
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aspirin withdrawal in patients treated with ticagrelor presenting with non-ST elevation myocardial infarction.
    Beigel R; Mazin I; Koifman E; Shechter M; Pres H; Shlomo N; Rosenberg N; Asher E; Matetzky S
    J Thromb Haemost; 2018 Apr; 16(4):663-669. PubMed ID: 29443445
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of lignocaine vs. opioids on antiplatelet activity of ticagrelor: the LOCAL trial.
    Fernando H; Duong T; Huynh K; Noonan J; Shaw J; Duffy SJ; Nehme Z; Smith K; Myles PS; Meikle PJ; Peter K; Stub D
    Eur Heart J; 2021 Oct; 42(39):4025-4036. PubMed ID: 34423354
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic, pharmacodynamic and pharmacogenetic profile of the oral antiplatelet agent ticagrelor.
    Teng R
    Clin Pharmacokinet; 2012 May; 51(5):305-18. PubMed ID: 22489610
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ticagrelor pharmacokinetics and pharmacodynamics in patients with NSTEMI after a 180-mg loading dose.
    Holm M; Tornvall P; Westerberg J; Rihan Hye S; van der Linden J
    Platelets; 2017 Nov; 28(7):706-711. PubMed ID: 28150519
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of Ticagrelor, Prasugrel, or Clopidogrel on Endothelial Function and Other Vascular Biomarkers: A Randomized Crossover Study.
    Ariotti S; Ortega-Paz L; van Leeuwen M; Brugaletta S; Leonardi S; Akkerhuis KM; Rimoldi SF; Janssens G; Gianni U; van den Berge JC; Karagiannis A; Windecker S; Valgimigli M;
    JACC Cardiovasc Interv; 2018 Aug; 11(16):1576-1586. PubMed ID: 29805112
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of morphine use on oral P2Y12 platelet inhibitors in acute myocardial infarction: Meta-analysis.
    Vaidya GN; Khan A; Ghafghazi S
    Indian Heart J; 2019; 71(2):126-135. PubMed ID: 31280824
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.